Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

Phase 2

Completed

Conditions: Refractory Anemia With Excess Blasts
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
de Novo Myelodysplastic Syndrome
Refractory Anemia
Refractory Anemia With Ring Sideroblasts
Polycythemia Vera
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Chronic Myelomonocytic Leukemia
Essential Thrombocythemia

Interventions: Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Radiation: Total-Body Irradiation

First Posted Date: 2006-11-10

Last Posted Date: 2020-01-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 77

Registration Number: NCT00397813

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
LDS Hospital, Salt Lake City, Utah, United States
🇺🇸
Veterans Administration Center-Seattle, Seattle, Washington, United States

Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease

Phase 2

Terminated

Conditions: Leukemia
Myelodysplastic Syndromes

Interventions: Biological: anti-thymocyte globulin
Drug: fludarabine phosphate
Drug: thiotepa
Procedure: peripheral blood stem cell transplantation
Radiation: total-body irradiation

First Posted Date: 2006-10-26

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 24

Registration Number: NCT00392782

Locations: 🇺🇸
Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States
🇺🇸
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States
🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

and more 6 locations

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

Phase 2

Completed

Conditions: Anti-p53 TCR-Gene

Interventions: Biological: anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes
Biological: aldesleukin
Biological: filgrastim
Drug: cyclophosphamide
Drug: fludarabine phosphate

First Posted Date: 2006-10-26

Last Posted Date: 2011-08-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00393029

Locations: 🇺🇸
National Institutes of Health, Bethesda, Maryland, United States

Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma

Not Applicable

Withdrawn

Conditions: Lymphoma

First Posted Date: 2006-10-19

Last Posted Date: 2012-03-16

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Registration Number: NCT00389506

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: umbilical cord blood transplantation
Radiation: total-body irradiation

First Posted Date: 2006-10-13

Last Posted Date: 2016-02-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT00387959

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease

Phase 2

Completed

Conditions: Hodgkin's Disease

Interventions: Drug: Gemcitabine
Drug: Fludarabine
Drug: Melphalan
Drug: Antithymocyte Globulin
Procedure: Allogeneic Stem Cell Infusion
Drug: Tacrolimus
Drug: Filgrastim (G-CSF)
Drug: Methotrexate

First Posted Date: 2006-10-11

Last Posted Date: 2018-05-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 52

Registration Number: NCT00385788

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients

Phase 2

Conditions: Multiple Myeloma

First Posted Date: 2006-09-29

Last Posted Date: 2006-09-29

Lead Sponsor: Nordic Myeloma Study Group

Target Recruit Count: 80

Registration Number: NCT00382694

Locations: 🇩🇰
Department of Haematology B, Aalborg Hospital, University of Aarhus, Aalborg, Denmark
🇩🇰
Department of Haematology, Herlev University Hospital, Herlev, Denmark
🇩🇰
Department of Haematology, Rigshospitalet, København Ø, Denmark

and more 3 locations

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Chronic Eosinophilic Leukemia
Blastic Phase Chronic Myelogenous Leukemia
Chronic Myelomonocytic Leukemia
Essential Thrombocythemia
Philadelphia Chromosome Negative Chronic Myelogenous Leukemia
Polycythemia Vera
Primary Myelofibrosis
Accelerated Phase Chronic Myelogenous Leukemia
Relapsing Chronic Myelogenous Leukemia

Interventions: Drug: fludarabine phosphate
Drug: triapine
Procedure: laboratory biomarker analysis

First Posted Date: 2006-09-28

Last Posted Date: 2015-01-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00381550

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Sargramostim
Drug: Rituximab

First Posted Date: 2006-09-27

Last Posted Date: 2016-01-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT00381004

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants

Phase 2

Completed

Conditions: Chronic Myelogenous Leukemia
Acute Myelogenous Leukemia
Chronic Lymphocytic Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome

Interventions: Device: Miltenyi reagent system
Other: FILGRASTIM (G-CSF)
Drug: Fludarabine
Drug: Cyclosporine
Drug: Cyclophosphamide

First Posted Date: 2006-09-20

Last Posted Date: 2021-06-16

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 116

Registration Number: NCT00378534

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy